key: cord-0871342-19t33njz
authors: Ladoire, Sylvain; Goussot, Vincent; Redersdorff, Emilie; Cueff, Adele; Ballot, Elise; Truntzer, Caroline; Ayati, Siavoshe; Bengrine-Lefevre, Leila; Bremaud, Nathalie; Coudert, Bruno; Desmoulins, Isabelle; Favier, Laure; Fraisse, Cléa; Fumet, Jean-David; Hanu, Roxana; Hennequin, Audrey; Hervieu, Alice; Ilie, Silvia; Kaderbhai, Courèche; Lagrange, Aurélie; Martin, Nils; Mazilu, Irina; Mayeur, Didier; Palmier, Rémi; Simonet-Lamm, Anne-Laure; Vincent, Julie; Zanetta, Sylvie; Arnould, Laurent; Coutant, Charles; Bertaut, Aurélie; Ghiringhelli, François
title: Seroprevalence of SARs-CoV-2 among the staff and patients of a French cancer centre after first lockdown: the canSEROcov study
date: 2021-02-27
journal: Eur J Cancer
DOI: 10.1016/j.ejca.2021.02.027
sha: 2912a01c60e329a5c730b47ad0c01e71f3d2fff6
doc_id: 871342
cord_uid: 19t33njz

BACKGROUND: In view of the potential gravity of SARS-CoV-2 infection for patients with cancer, epidemiological data are vital to assess virus circulation among patients and staff of cancer centres. We performed a prospective study to investigate seroprevalence of SARS-CoV-2 antibodies among staff and cancer patients at a large cancer centre, at the end of the period of first national lockdown in France, and to determine factors associated with the risk of SARS-CoV-2 infection. METHODS: After the first lockdown, all medical and non-medical staff, and all patients attending the medical oncology department were invited to undergo serological testing for SARS-CoV-2 between 11 May and 30 June 2020. All participants were also invited to complete a questionnaire collecting data about their living and working conditions, and for patients, medical management during lockdown. FINDINGS: A total of 1,674 subjects (663 staff members, 1011 patients) were included. Seroprevalence was low in both staff (1.8%) and patients (1.7%), despite more features of high risk for severe forms among patients. None of the risk factors tested in our analysis (working or living conditions, comorbidities, management characteristics during lockdown) was found to be statistically associated with seroprevalence in either staff or patients. There was no significant difference in the proportion of symptomatic and asymptomatic subjects between staff and patients. Only fever, loss of smell and loss of taste were significantly more frequent among seropositive patients, in both staff and patients. INTERPRETATION: We report very low seroprevalence of antibodies against SARS-CoV-2 in the staff (caregiving and non-caregiving) and patients of a large cancer care centre in which strict hygiene, personal protection and social distancing measures were implemented.

Background :

In view of the potential gravity of SARS-CoV-2 infection for patients with cancer, epidemiological data are vital to assess virus circulation among patients and staff of cancer centres. We performed a prospective study to investigate seroprevalence of SARS-CoV-2 antibodies among staff and cancer patients at a large cancer centre, at the end of the period of first national lockdown in France, and to determine factors associated with the risk of SARS-CoV-2 infection.

After the first lockdown, all medical and non-medical staff, and all patients attending the medical oncology department were invited to undergo serological testing for SARS-CoV-2 between 11 May and 30 June 2020. All participants were also invited to complete a questionnaire collecting data about their living and working conditions, and for patients, medical management during lockdown.

A total of 1,674 subjects (663 staff members, 1011 patients) were included. Seroprevalence was low in both staff (1.8%) and patients (1.7%), despite more features of high risk for severe forms among patients. None of the risk factors tested in our analysis (working or living conditions, comorbidities, management characteristics during lockdown) was found to be statistically associated with seroprevalence in either staff or patients. There was no significant difference in the proportion of symptomatic and asymptomatic subjects between staff and patients. Only fever, loss of smell and loss of taste were significantly more frequent among seropositive patients, in both staff and patients.

We report very low seroprevalence of antibodies against SARS-CoV-2 in the staff (caregiving and noncaregiving) and patients of a large cancer care centre in which strict hygiene, personal protection and social distancing measures were implemented.

In December 2019, China 1 and very soon, the rest of the world 2 , were faced with an epidemic of coronavirus disease 2019 (COVID-19) caused by a new beta coronavirus, named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) 3 . France was among the hardest hit countries in Europe, with more than 200,000 documented cases and more than 30,000 deaths at the end of the first period of national lockdown 4 . To limit the spread of the epidemic, the French government decided to implement a nationwide lockdown, which was in place from 17 March to 11 May 2020.

During this period, and even now, French hospitals also took a number of measures to limit the spread of the virus within the hospital, in order to ensure continuity of care, but at the same time, to protect patients and staff as much as possible. Particular attention was paid from the outset to the most vulnerable patients and to subjects with comorbidities, including patients with cancer (whether on or off treatment). Indeed, these groups initially appeared to be at highest risk of developing the infection 5, 6 , particularly more severe, not to say fatal forms [7] [8] [9] [10] [11] [12] [13] . A retrospective series of 302 cancer patients with suspected COVID-19 in France found that that the death rate at 30 days after diagnosis was high in patients both with and without documented SARS-COV-2 on RT-PCR 14 . Similarly, a recent prospective, observational study from a network of cancer centres in the United Kingdom reported that most cancer patients had a mild disease course, but 28% died, suggesting high number of severe forms. The risk factors associated with mortality were age, male sex and comorbidities (hypertension, cardiovascular disease), whereas cytotoxic chemotherapy or other anticancer treatment was not associated with an increased risk of death 15 . Similar data have been published in French patients 16 . National and international recommendations have been issued regarding the optimal management of cancer patients during the COVID-19 pandemic [17] [18] [19] [20] . Yet, while numerous publications have reported the prognosis of cancer patients hospitalized for SARS-Cov-2 infection, few studies have investigated the incidence of infection in patients and staff of cancer care centres 21 .

Moreover, these studies had potential for bias, notably due to the inclusion of a population of patients that is not representative of the wide diversity of cancer patients, or inclusion of only hospitalized patients, who potentially have more severe and advanced disease, and thus, a higher risk of death. Furthermore, in published studies to date, the diagnosis was made by RT-PCR, which is sensitive for the detection of the initial phase of infection, and also practical, notably in terms of conservation and transport of samples 9, 22 . Conversely, it is quite possible that many asymptomatic or mildly symptomatic patients may have escaped diagnosis, contributing to the spread of the virus [23] [24] [25] . Compared to RT-PCR, serological tests in search of specific anti-SARS-CoV-2 antibodies (IgM and IgG) make it possible to study cumulative prevalence of infection, due to the persistence of circulating antibodies beyond the infectious period in patients who were infected, and even after recovery 23 26,27 . Evaluating the cumulative prevalence of SARS-CoV-2 infection is useful from an J o u r n a l P r e -p r o o f epidemiological point of view, to estimate the degree of dissemination of the virus, to highlight pathways of contamination, and to study immunity in exposed populations 28,29 . In this cross-sectional study, performed shortly after the end of the first lockdown in France, we investigated seropositivity for SARS-CoV-2 in a large cancer care centre in one of the regions of France that was hardest hit by the epidemic (Burgundy Franche-Comté, Eastern France) 4 . We aimed to assess seroprevalence in both staff (medical and non-medical) and patients (medical oncology patients) of a single, dedicated cancer centre, with the following objectives: (i) to describe the spread of infection among the different categories of staff and in a large population of patients being managed for cancer; (ii) using dedicated individual questionnaires, we sought to identify factors (professional, social, demographic, medical or related to living conditions during confinement) associated with SARS-CoV-2 infection in both groups; (iii) indirectly, we aimed to evaluate the efficacy of the preventive measures implemented during lockdown in the two groups who had different risks of SARS-CoV-2 infection, and different risks of developing severe forms of the disease.

The location of the cancer care centre, epidemiology of SARS-CoV-2 in the region, and safety measures implemented at our institution are described in detail in the Supplemental Appendix.

All employees, i.e. 860 staff members, were invited to participate in the study. Assuming at positivity rate of around 10% (according to the literature at the time of the study design), a non-response rate of 20%, a sample size of 860 would produce a 2-sided confidence interval with a precision of 2.3%.

Regarding patients, we chose to include all patients attending our institution from 25 May to 30 June 2020, irrespective of cancer location, stage or treatment. We aimed to include about 1000 patients over the study period. Assuming a lower positivity rate of 5% (due to possibly lower exposure), and a non-response rate of 25%, this would produce a two-sided 95% confidence interval with a precision of 1.6%.

The study was approved by the internal scientific committee of the Georges-Francois Leclerc Cancer Centre, and by its internal Ethics Committee, as well as by a national Ethics Committee (CPP Sud-Ouest et Outremer 1). The questionnaires destined for the staff and those for the patients were developed jointly by a group comprising oncologists, biologists and epidemiologists from our centre, specifically for the purposes of this study. For all patients, data relating to their cancer and treatment was retrieved from the medical files.

All serum samples were analysed in the clinical biology unit of the Georges-Francois Leclerc cancer centre. We measured SARS-CoV-2 total antibodies on the fully-automated cobas e411 analyzer (Roche Diagnostics) using the novel Elecsys® Anti-SARS-CoV-2 electrochemiluminescence immunoassay (Roche Diagnostics) for the qualitative detection of SARS-CoV-2 antibodies in human serum and plasma. The IVD CE-marked Elecsys® assay uses a modified double-antigen sandwich immunoassay using recombinant nucleocapsid protein (N), which is geared towards the detection of late, mature, high affinity antibodies independent of the subclass. It is a total SARS-CoV-2 antibody assay (IgA, IgM, and IgG) detecting predominantly, but not exclusively, IgG. This test was validated 

Quantitative variables are described as mean±standard deviation (SD) or median (range), and were dichotomized according to the median or a clinically relevant threshold. Qualitative variables are described as number (percentage). The number of missing data is indicated for each variable. The prevalence of seropositivity is expressed as a percentage with the associated 95% Confidence Interval (CI). Comparisons between groups were performed using the appropriate parametric or nonparametric tests, according to the number of groups compared and the normality (or not) of distributions in each group. Factors associated with seropositivity among staff members and among patients were investigated using univariate logistic regression. The small number of events precludes multivariate analysis. All analyses were performed by the Methodology & Biostatistics Unit of the Georges-Francois Leclerc cancer centre using SAS version 9.4 (SAS Institute Inc., Cary, NC). A p-value <0.05 was considered statistically significant.

The detailed characteristics and questionnaire results for the staff and patients are presented in Supplemental Appendix 1-3.

A total of 663 staff members (80.3% of all staff) completed the study questionnaire and had a blood sample for serological testing. The main characteristics of the participating staff members, and their serological results are shown in Table 1 and Supplemental Appendix 1. Briefly, there were 522 (78.7%) women and 141 (21.3%) men. Average age was 38.5 (±11.6) years. The professional categories of employees are described in Figure 1A and Supplemental Appendix 1.

During lockdown, 9.1% of staff worked from home all the time, while 54.5% worked as usual at the cancer care centre, and 36.4% worked partially from home ( Figure 1B ). In total, 105 employees (15.8%) reported having worked in the dedicated COVID unit during lockdown ( Figure 1C ). As regards exposure to risk of SARS-CoV-2 infection, 333 employees (50.2%) reported that they were in contact with patients during their routine work, outside the dedicated COVID unit ( Figure 1D ). Among those who reported being in contact with patients during lockdown, 98% said that they wore a mask (on average, 86% of the time, Figure 1F ). Despite the comorbidities recorded among the staff members ( Figure 2A and Supplemental Appendix 1), no employee had a severe form of COVID-19 infection during lockdown. A total of 324 employees (48.9%) reported at least one symptom (described in Figure 2B and supplemental Appendix 1).

In total, only 12 of the 663 employees were seropositive, yielding a seroprevalence of 1.8% (Supplemental Appendix 1). None of the seropositive employees had experienced severe COVID-19.

Three of them (25%) had been tested positive during lockdown (by nasal swab and RT-PCR testing), and overall, they were the only 3 employees with a positive nasal swab test in the whole cohort of 663 participants (3/663: 0.45%) ( Figure 2D ). Among the 12 seropositive employees, 6 were caregivers (3 physicians, 1 resident, 2 nurses), 3 were medico-technical staff (3 technicians from radiology/nuclear medicine), 1 secretary and 2 basic research staff members ( Figure 1A) . A majority of them (66.7%) worked on-site as normal during lockdown ( Figure 1B) . Only 2 of the seropositive employees had worked in the dedicated COVID unit in the centre ( Figure 1C ). Of the 9 seropositive patients who worked in contact with patients during lockdown, all of them (100%) reported having worn a mask systematically when in contact with patients ( Figure 1F ).

There was no significant difference between seropositive and seronegative staff members in terms of staff category, working conditions (working from home or not), contact with patients, working in the Regarding symptoms, there was a numerically higher rate of symptoms among seropositive employees (75% vs 48.4% ; p=0.06), but 25% of seropositive staff declared that they had experienced no symptoms. Among the symptoms recorded, only fever (p=0.019), loss of smell (p=0.0022), loss of taste (p=0.0016) and muscle cramps or pains (p=0.0087) were significantly more frequently present in seropositive staff. The total number of symptoms was also higher in seropositive employees ( Figures 2B-C) .

By univariate analysis, none of the variables tested (namely sex, staff category, working in contact with patients, working in COVID unit, working from home, contact with known COVID-positive person) was statistically associated with positive SARS-CoV-2 serology (Supplemental Appendix 2), but given the lower than expected number of events, and the resulting lack of statistical power, no robust conclusions can be drawn from this analysis.

In total, 1011 patients from the Medical Oncology department were included, completed the study questionnaires, and had a blood sample taken for SARS-CoV-2 serological testing. The main characteristics of the patients included in the study are shown in Table 2 (and Supplemental Appendix 3). Regarding the type of cancer, breast cancer was the most frequent (45.2%), followed by digestive, urological and gynaecological tumours (Figure 3A ). At the time of the blood test, 38% of patients were attending a consultation, 41% were attending the outpatient unit, and 21% were inpatients ( Figure 3B ). Most were receiving chemotherapy (alone or in association with targeted therapy, immunotherapy or radiotherapy) ( Table 2) .

Among the 1,011 patients included, more than half (51.4%) had one or more comorbidities ( Figure   3C As for the employees, there was also no significant difference in terms of age, sex, comorbidities, smoking status or chronic (non-cancer) medication ( Figure 3C and Supplemental Appendix 3) .

Attendance at the cancer care centre during lockdown did not differ between seropositive and seronegative patients (Figure 4A) , and there was no difference in terms of hospital admissions, consultations, radiotherapy, surgery, or number of chemotherapy sessions performed (Supplemental Appendix 3). There was also no difference in the rate of cancellation or postponement of treatments or consultations during lockdown (Figures 4B-C) .

Regarding symptoms, seropositive patients did not have significantly more symptoms than seronegative patients (p=0.34), and 47% of seropositive patients said they experienced no symptoms, whereas 41.4% of seronegative patients reported having had symptoms during lockdown ( Figure 3D ). Among the symptoms reported, as for employees, fever (p<0.0001), loss of smell (p=0.001) and loss of taste (p=0.0068) were significantly more frequent among seropositive patients, as was the overall number of symptoms reported (p=0.03) (Figure 3D-E) .

Among the 7 seropositive patients who had undergone RT-PCR testing from a nasal swab during lockdown, 2 of them had received a negative result. Among seronegative patients who had had RT-PCR testing of a nasal swab during lockdown, none had a positive RT-PCR result ( Figure 3F) .

By univariate analysis, none of the variables tested (i.e. sex, ongoing anti-cancer treatment, comorbiditiy, attendance at the cancer care centre during lockdown, cancellation or postponement of treatment or consultation) was significantly associated with seropositivity (Supplemental Appendix 4). Here again, given the lower than expected number of events, and the resulting lack of statistical power, no robust conclusion can be drawn from this analysis.

We compared the main characteristics associated with the risk of SARS-CoV-2 infection, as well as the symptoms presented, between staff and patients. The rate of seropositivity was the same in both groups, even though the patients were significantly older (p<0.0001), with more men (p<0.0001) and more frequent comorbidities (p<0.0001), in particular more frequent hypertension, diabetes or chronic disease (other than cancer) (Supplemental Appendix 5). Patients more often lived alone during lockdown (p<0.0001), and reported fewer contacts with known SARS-CoV-2-positive individuals (p<0.0001) compared to staff members. Regarding symptoms, patients reported significantly fewer symptoms, but significantly more loss of taste, breathlessness and muscle pain.

Conversely, the employees more frequently reported cough and headache.

The cut-off index (COI) for seropositivity did not differ significantly between patients and staff, regardless of whether they had symptoms or not (Supplemental Figure 1) .

To the best of our knowledge, this is the first prospective study of SARS-CoV-2 seroprevalence including all the employees, as well as medical oncology patients from a large cancer centre at the end of a period of national lockdown. Given the high risk of severe disease among cancer patients, epidemiological data among cancer patients themselves and among those who care for them are of utmost importance.

Our study found a low rate of seropositivity for SARS-CoV-2 among both staff (medical and nonmedical) and patients in our centre, and we failed to find any factor that was significantly associated with the risk of seropositivity, most likely due to a lack of power, given the lower than expected number of positive cases. Interestingly, this low seropositivity rate (<2% in all those tested) was found in both groups, even though the patients, most of whom were receiving ongoing cancer treatment, were generally older, more often male, with more comorbidities. The low seropositivity rate observed in our patients was probably not biased by uncounted patients who died of COVID-19.

Indeed, as described in the Supplemental Appendix, our COVID-19 dedicated hospitalization sector received all the patients from our cancer centre who were suspected of being infected, and only housed a total of 11 patients (all PCR positive) during the period from 17 March to 11 May 2020. Six of these patients died of respiratory complications. The low seropositivity observed here is in line with, not to say lower than the projected rates for the general population in France at that time 31 , even though serological testing generally reveals more cases than CT scan or PCR testing.

The majority of papers published to date investigating SARS-CoV-2 infection rates in cancer patients reported overall incidence, the clinical presentation of symptomatic forms, the incidence of severe forms (and risk factors thereof), as well as prognosis in this particularly vulnerable population. Since the clinical signs of mild or asymptomatic forms of COVID-19 are not specific, and similar to those of several other viruses responsible for seasonal respiratory infections, serological testing can help to diagnose subjects who remain asymptomatic at the acute phase, in addition to symptomatic individuals 32 . Mathematical models performed during the first wave estimated that only 2.9% of infected individuals in France were hospitalized 31 . Based on this estimation, and on the reported cumulative cases of hospitalized COVID-19 patients as of June 30th, 2020, we estimate that approximately 6% of the total population of our region (Burgundy-Franche Comté) would have been infected when we finished our study. These estimates support the posit that seroprevalence was lower than expected in our 2 study populations.

A study performed in Wuhan, China between March and April 2020 reported that by oropharyngeal swab testing for SARS-CoV-2 nucleic acid by RT-PCR and/or serum specific antibody testing (IgM and IgG), the rate of asymptomatic infection was 2.9% in patients with cancer, and 2.1% among their caregivers 33 , which is very close to the rates observed in our study. Another seroprevalence study in Wuhan found a seropositivity rate between 3.2 and 3.8%, with higher rates observed in those who attended the hospital more frequently 26 .

Regarding the staff, published reports of SARS-CoV-2 seroprevalence mostly stemmed from caregivers directly involved in patient care, and also generally mixed groups of health professionals working in departments with very different clinical activity. Accordingly, published series from Europe from the first wave of the pandemic reported higher seroprevalence rates (at around 5 to 10%) than observed in our study [34] [35] [36] [37] [38] , but with high proportions of asymptomatic subjects, as also observed in our cohort. The main factor associated with infection was generally the fact of working in contact with SARS-CoV-2-infected patients in dedicated COVID units [35] [36] [37] 39, 40 . The fact that our institution implemented a protective "COVID-free" policy, whereby we did not receive patients with suspected SARS-CoV-2 infection for first-line treatment, likely explains the low spread of infection among the caregiving and non-caregiving staff.

In our study, we did not identify any work-related or out-of-hospital factor that was statistically associated with positivity serology, which could also reflect the wide diversity of ways in which people may be contaminated (be it patients or employees).

We observed a low seropositivity rate in both employees and oncology patients, underlining that when there is a lockdown, and when strict hygiene measures are implemented in the hospital context, the spread of the virus is negligible among patients and among staff working in the hospital environment, even those who are in contact with patients. This suggests that with appropriate protective measures adequately implemented within hospitals welcoming cancer patients, and by the general population, the delivery of care to cancer patients may continue as normal, without any apparent excess risk of SARS-CoV-2 infection. Recently, a study of systematic screening for SARS-CoV-2 RNA by nasal swab and RT-PCR testing in cancer patients at a large tertiary care hospital in Austria that implemented strict measures for hygiene, personal protection and social distancing, reported a very low rate (0.4%) of infection in patients 41 . Interestingly, the same team also reported low seropositivity in a small cohort of patients and health professionals in oncology (3.6% and 3.2% respectively) 42 . The protective measures put in place were very similar to those implemented in our centre, and demonstrate that it is possible to protect patients being treated for (or who were previously treated for) cancer, but also caregiving and non-caregiving staff at the height of the epidemic by means of simple measures, thus making it possible to continue delivering care to patients in need, in acceptable conditions of safety.

Regarding the utility of serological testing, beyond the epidemiological descriptive value, the persistence of antibodies in the long term is still the subject of some debate, and prospective longterm follow-up of seropositive subjects is warranted to ascertain whether humoral immunity to SARS-CoV-2 remains present. Recent data seem to show lower seroconversion in cancer patients compared to health care workers 43 , but the data published so far are discordant 44 . In our study, the cut-off index (COI) for seropositivity (which does not, however, constitute an exact quantitative determination of antibodies) did not differ significantly between patients and staff, regardless of whether they had symptoms or not, which pleads in favor of a similar humoral response between these 2 populations. Furthermore, the level of neutralizing antibody activity required to confer lasting immunity is also unknown. In this context, it is thus impossible to say with certainty whether the presence of antibodies against SARS-CoV-2 (especially at low levels) will protect against reinfection with the virus. Future studies are urgently needed to determine the threshold of antibodies, and the level of neutralizing activity that are required to achieve protective immunity.

We confirm in this study that the symptoms experienced in SARS-CoV-2 are not specific, with a high proportion of seropositive subjects having experienced no symptoms, and conversely, numerous seronegative subjects who reported symptoms. This is was more predominant among the patients, in whom cancer may lead to the same respiratory or general signs as SARS-CoV-2 infection. Among the symptoms reported, only loss of taste and smell seem to be specifically associated with seropositivity, both among patients and employees, as has been widely reported among all the populations studied to date 45 , including health-care workers [36] [37] [38] . Apart from these two specific signs, our results highlight the difficulty of relying on the presence or absence of various symptoms as a means of identifying subjects who are infected, in a cancer context.

Our study has several strengths compared to other available data in the literature. Firstly, we included over 80% of all staff in our cancer care centre, including both caregivers and non-caregiving staff, employees who were in contact with patients as well as those who were not, and different levels of presence on site in the centre during national lockdown in France. Secondly, the diagnostic test used in our study is automated, reproducible, sensitive and specific (CV of 3.8% for positive internal control; sensitivity of 100% 14 days post-PCR confirmation; specificity greater than 99.8% with no cross-reaction with Coronavirus HKU1, NL63, 229E or OC43). These performances have been confirmed in numerous studies, including one head-to-head comparison of this test with other available immunoassays 46 . Moreover, the same assay was used for all the subjects included, both among the employees and the patients, which is not generally the case in studies using RT-PCR (because of changes in available tests during the epidemic) and/or CT scan (different machines and interpretation by different radiologists). Furthermore, our study was conducted prospectively in a large cohort of subjects with specific questionnaires developed ad hoc to obtain the same J o u r n a l P r e -p r o o f information for all participants. The study procedures (questionnaires and blood tests) were implemented among staff and patients over a short time period immediately after the end of the first lockdown, thus providing an accurate snapshot of the spread of the virus at that particular epidemiological timepoint. Our results thus stem from a more homogeneous patient population than included in previous reports in the literature, and a population that is representative of real-life management in oncology, rather than being limited to in-patients (who generally have more severe disease).

Conversely, our study also has some limitations. Firstly, there was a low number seropositive participants, resulting in low power for the statistical analyses of factors associated with SARS-CoV-2 infection. This underlines the importance of large-scale pooling of serology data on SARS-CoV-2 to broaden our understanding of the epidemiology of this virus in hospital staff and among vulnerable individuals such as those with cancer. Second, the data recorded were self-reported and there may thus be potential for declaration bias. However, many of the variables reported here are not recorded in the patients' medical files and therefore, a self-report questionnaire was the only way to access the information.

In conclusion, this prospective study shows that despite being geographically located in one of the regions hardest hit by the epidemic in France, the seropositivity rate for SARS-CoV-2 infection at the end of lockdown was very low in our cancer care centre, among both staff and medical oncology patients. The epidemiological data recorded in this study suggest that lockdown and strict application of hygiene measures, personal protection and social distancing were effective in our hospital, which was not a priority destination for patients infected with or suspected of COVID-19. These measures appear to have been effective during the first epidemic wave, and could guide recommendations in case of persistence of the epidemic, to enable for cancer centres to continue delivering care, while protecting patients and employees as much as possible. J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Global transmission network of SARS-CoV-2: from outbreak to pandemic

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak

High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study

Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study

Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies

High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group

Cancer guidelines during the COVID-19 pandemic

Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal

Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence

Characteristics and outcome of SARS-CoV-2 infection in cancer patients

Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding

Identification of RT-PCR-Negative Asymptomatic COVID-19 Patients via Serological Testing. Front

Prevalence of Asymptomatic SARS-CoV-2 Infection

Asymptomatic SARS-CoV-2 infection

Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China

Humoral Immune Response to SARS-CoV-2 in Iceland

Assessing the extent of SARS-CoV-2 circulation through serological studies

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Estimating the burden of SARS-CoV-2 in France

An analysis of cancer patients with asymptomatic infection of SARS-CoV-2 in a cancer center in Wuhan

Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital

Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study

Risk of COVID-19 in health-care workers in Denmark: an observational cohort study

SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden

Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium

SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients

Seroprevalence of SARS-CoV-2 Among Frontline Healthcare Personnel During the First Month of Caring for COVID-19 Patients

SARS-CoV-2 Testing in Patients With Cancer Treated at a Tertiary Care Hospital During the COVID-19 Pandemic

SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic

Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19

Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2

COVID-19 and anosmia: A review based on up-to-date knowledge

Anti-SARS-CoV-2 immunoassays were funded by Roche Diagnostics France, but the company had no role in the study design and writing of the paper.The authors thank Fiona Ecarnot, PhD (EA3920, University of Franche-Comté, Besançon, France) for translation and editorial assistance *** **